Windlas standalone Q1FY27: revenue +18% YoY, PAT flat as material costs squeeze margins

Windlas Biotech's standalone Q1 FY27 (quarter ended June 30, 2026) revenue rose 18.1% YoY to ₹248.1 Cr from ₹210.1 Cr, continuing the growth trajectory from FY26 (full-year revenue growth of 19%, past ₹900 Cr). Profit after tax, however, was effectively flat YoY at ₹17.65 Cr versus ₹17.66 Cr a year ago (-0.06%), even as it rose 10.4% sequentially from ₹15.99 Cr in Q4 FY26. Basic EPS ticked up marginally to ₹8.46 from ₹8.43 YoY (+0.4%), helped by a lower share count after the ₹47 Cr tender-offer buyback (470,000 shares at ₹1,000) completed in April. No exceptional items appear in either period, so the YoY comparison is clean.

The gap between strong topline growth and stagnant profit is a margin story. Net profit margin (on total income) compressed to 6.97% from 8.20% a year ago, and EBITDA margin fell to 10.75% from 12.63%. Cost of materials consumed jumped to 68.0% of revenue from 59.7% in Q1 FY26, and employee benefit expense rose 37.9% YoY to ₹44.4 Cr (17.9% of revenue versus 15.3%) — both outpacing the 18.1% revenue growth and absorbing the benefit of higher volumes. Sequentially margins improved modestly versus Q4 FY26's 6.58% NPM/10.60% OPM, but the YoY compression is the primary read.

The stock went into the print at ₹823, down 0.8% over the past month of trading.

For context: PAT has now risen for 2 consecutive quarters; revenue is at a 6-quarter high.

Management's prior guidance flagged "operational efficiencies" and capability enrichment as FY27 priorities alongside CDMO/export-led growth and new capacity from Plant 6, expected to commercialize in H1 FY27; this quarter's material and employee cost inflation runs somewhat counter to that efficiency framing, though Plant 6 has yet to contribute. No street consensus estimates for this quarter turned up in a web search and no management press release was available for this filing, so vsStreet is unknown. A structural change also affects future comparability: following the dissolution of non-operating US subsidiary Windlas Inc. effective March 31, 2026, the company has stopped preparing consolidated statements from Q1 FY27 — this quarter's standalone print is the full and only basis, and the impact of the change is likely immaterial since the subsidiary was dormant. Separately, the company paid out ₹130.0 Cr (₹6.30/share) as FY26 dividend on July 31, 2026, per AGM approval.